Evidence map›Paper›PMID 41452872›Full record

ArticlePloS one2025

A protocol for development of a microsimulation model platform to evaluate the potential benefits, harms, and cost-effectiveness of risk-tailored melanoma screening.

Kirstie G McLoughlin, Caroline G Watts, Stephen Wade, Amelia K Smit, H Peter Soyer, Pablo Fernandez-Peñas, David C Whiteman, Pascale Guitera, Gillian Reyes-Marcelino, Karen Canfell and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kirstie G McLoughlinThe Daffodil Centre, The University of Sydney, and Cancer Council New South Wales, Sydney, New South Wales, Australia.
Caroline G WattsThe Daffodil Centre, The University of Sydney, and Cancer Council New South Wales, Sydney, New South Wales, Australia.
Stephen WadeThe Daffodil Centre, The University of Sydney, and Cancer Council New South Wales, Sydney, New South Wales, Australia.
Amelia K SmitThe Daffodil Centre, The University of Sydney, and Cancer Council New South Wales, Sydney, New South Wales, Australia.
H Peter SoyerFrazer Institute, The University of Queensland, Dermatology Research Centre, Brisbane, Queensland, Australia.
Pablo Fernandez-PeñasThe University of Sydney, Faculty of Medicine and Health, Westmead Clinical School, New South Wales, Australia.ORCID https://orcid.org/0000-0003-4882-1564
David C WhitemanDepartments of Population Health and Computational Biology, QIMR Berghofer Medical Research Institute, Queensland, Australia.
Pascale GuiteraMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Gillian Reyes-MarcelinoThe Daffodil Centre, The University of Sydney, and Cancer Council New South Wales, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-3250-0961
Karen CanfellThe Daffodil Centre, The University of Sydney, and Cancer Council New South Wales, Sydney, New South Wales, Australia.
Anne E CustThe Daffodil Centre, The University of Sydney, and Cancer Council New South Wales, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-5331-6370
Michael CaruanaThe Daffodil Centre, The University of Sydney, and Cancer Council New South Wales, Sydney, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In populations of European descent, melanoma is a high burden cancer in terms of incidence and healthcare costs, with early detection linked to better prognosis. There is no organised population screening program for melanoma in most countries, as more information is required about the potential benefits, harms and costs of population-based screening to develop policy. To assess the cost-effectiveness of a potential risk-tailored organised melanoma screening program in Australia, we have developed a protocol for a comprehensive microsimulation model (Policy1-Melanoma) that can evaluate multiple potential screening strategies. We outline the development of Policy1-Melanoma, a natural history model developed to be flexibly used to evaluate a range of scenarios related to melanoma screening, diagnosis, surveillance and management. We specify the types of data sources used for calibration and validation of Policy1-Melanoma, and the steps in this process.

Indexed as

Early Detection of CancerMass ScreeningMelanomaSkin NeoplasmsAustraliaComputer SimulationCost-Benefit AnalysisHumansRisk Assessment

Identifiers

PMID41452872
PMCPMC12742747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.